Clinical Trials Logo

Clinical Trial Summary

There is no bedside imaging technique that can quantify dynamic bowel perfusion with high soft tissue contrast and sensitivity in necrotizing enterocolitis (NEC). Our goal is to assess the feasibility of utilizing contrast-enhanced ultrasound (CEUS) in bedside monitoring of bowel perfusion in NEC. Patients with suspected or diagnosed NEC will be recruited for the study. Following parental consent, the subject will undergo CEUS, performed separately from any clinically indicated conventional US, in the ICU. Subjects will be scanned with CEUS at two different time-points (at the time NEC is first suspected or diagnosed and at time of MRI scan). The CEUS scans will be interpreted by the sponsor-investigator. The study will be conducted at one site, The Children's Hospital of Philadelphia. It is expected that up to 100 subjects will be enrolled per year, for up to two years, for a total enrollment of up to 200 subjects.


Clinical Trial Description

Early detection of ischemia and necrotic bowel which leads to perforation is vital in improving morbidity and mortality associated with NEC. Abdominal radiography, the standard imaging algorithm for monitoring of NEC, has a low sensitivity of 40% in the diagnosis of severe NEC with necrotic bowel. There is a dire need to introduce better imaging tools such as CEUS to the clinical setting that can detect NEC at an early stage and prompt therapeutic implementation. CEUS enables safe, serial monitoring of dynamic quantification of bowel perfusion at the bedside. Sulfur hexafluoride lipid-type A microspheres (LumasonTM, Bracco Inc) is an FDA-approved ultrasound contrast agent. The study duration per subject will be approximately 15 minutes including the time to prepare LumasonTM contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of LumasonTM. CEUS will be performed at the time of suspected or diagnosed NEC, and at the time of surgery (for subjects undergoing surgery as part of clinical care) or at short-term follow-up of clinical condition (approximately 1 week after the first scan) for a total of two CEUS exams of 1 hour and 15-minute duration each. Injection of LumasonTM contrast agent will be performed via the existing peripheral intravenous line or central line using the FDA-recommended dose of up to 0.03 mg/kg. Contrast-agent injection will be performed twice per CEUS scan to ensure image quality and test reproducibility. In the case of more stable patients without an IV line, a peripheral IV line will be started to conduct the investigational CEUS. Two bolus injections will performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam. Qualitative analysis with visual assessment and quantitative analysis of the acquired CEUS scans will be performed and interpreted by the PI. The scans will be assessed for diagnostic quality of images, artifacts encountered, and the presence of additional contributory diagnostic information. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03549507
Study type Interventional
Source Children's Hospital of Philadelphia
Contact Misun Hwang, MD
Phone 267-425-7129
Email hwangm@chop.edu
Status Recruiting
Phase Phase 3
Start date November 4, 2020
Completion date June 12, 2024

See also
  Status Clinical Trial Phase
Completed NCT03926390 - Gut Priming With Oral Bovine Colostrum for Preterm Neonates; Randomized Control Trial N/A
Completed NCT03111329 - Does Routine Assessment of Gastric Residuals in Preterm Neonates Influence Time Taken to Reach Full Enteral Feeding? N/A
Recruiting NCT05619055 - The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis
Completed NCT04977817 - Probiotics/TPN in the NICU
Completed NCT03136172 - Monitoring of Systemic or Organ Perfusion for Preterm Infants
Completed NCT04719546 - Risk Factors of Necrotizing Enterocolitis in Premature Newborns
Recruiting NCT03366584 - The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates Phase 4
Recruiting NCT04083638 - The Relationship Between Erythrocyte Transfusion and Nutrition and Necrotizing Enterocolitis in Preterm Infants
Not yet recruiting NCT05710575 - Role of Probiotic Use in Outcomes of Premature Birth N/A
Recruiting NCT05121753 - Infant Formula Feeding and Necrotizing Enterocolitis in Newborns
Recruiting NCT03997266 - NICU Antibiotics and Outcomes Trial Phase 4